Last reviewed · How we verify
Radiofrequency
Radiofrequency is a Small molecule drug developed by Assiut University. It is currently in Phase 1 development.
Radiofrequency refers to the oscillation rate of an alternating electric current or voltage in the frequency range from around 20 kHz to 300 GHz. In the context of medical treatment, radiofrequency is used in interventions such as ablation for conditions like lung cancer, as studied in clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Radiofrequency |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Conventional vs Pulsed RF in Coccydynia (NA)
- Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI
- Left Atrial Arrhythmia Substrate Identification After Confirmed durABLE Pulmonary Vein Isolation (NA)
- Image Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Osteoarthritis (NA)
- Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin (NA)
- Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
- Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors
- The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiofrequency CI brief — competitive landscape report
- Radiofrequency updates RSS · CI watch RSS
- Assiut University portfolio CI
Frequently asked questions about Radiofrequency
What is Radiofrequency?
Who makes Radiofrequency?
What development phase is Radiofrequency in?
Related
- Manufacturer: Assiut University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing